Pages that link to "Q35801437"
Jump to navigation
Jump to search
The following pages link to PDE4 inhibitors in COPD--a more selective approach to treatment (Q35801437):
Displaying 29 items.
- Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Q24202545) (← links)
- Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Q24234493) (← links)
- Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Q24243560) (← links)
- Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias (Q24337832) (← links)
- Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control (Q36183282) (← links)
- Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease (Q36535986) (← links)
- Phosphodiesterase 4D and heart failure: a cautionary tale (Q36596672) (← links)
- Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment (Q36792648) (← links)
- Phosphodiesterases regulate airway smooth muscle function in health and disease (Q36820316) (← links)
- Treating COPD with PDE 4 inhibitors. (Q37082594) (← links)
- Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis (Q37128056) (← links)
- Pharmacological control of neutrophil-mediated inflammation: strategies targeting calcium handling by activated polymorphonuclear leukocytes (Q37385606) (← links)
- Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review). (Q37652125) (← links)
- Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management (Q37880077) (← links)
- Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease? (Q37895710) (← links)
- Pharmacological approaches to regulate neutrophil activity. (Q38089635) (← links)
- Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs (Q38595360) (← links)
- The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? (Q38879975) (← links)
- Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. (Q39322017) (← links)
- MKP-1 negative regulates Staphylococcus aureus induced inflammatory responses in Raw264.7 cells: roles of PKA-MKP-1 pathway and enhanced by rolipram (Q41981484) (← links)
- Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD. (Q43061572) (← links)
- Roflumilast: systemic therapy for chronic obstructive pulmonary disease (Q43061644) (← links)
- Developments in the field of allergy in 2016 through the eyes of Clinical and Experimental Allergy (Q45070970) (← links)
- Recommendations for the pharmacological treatment of COPD: questions and answers. (Q47272746) (← links)
- Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Q47551310) (← links)
- Metabolomic profiles of current cigarette smokers (Q50286187) (← links)
- Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model (Q51109588) (← links)
- Pd-mediated new synthesis of pyrroles: their evaluation as potential inhibitors of phosphodiesterase 4 (Q84280335) (← links)
- Progress in the mechanism and targeted drug therapy for COPD (Q101038363) (← links)